Precision Care (PC) interventions, developed with guidance from a Community Advisory Board
(CAB), will be piloted in a Randomized Clinical Trial (RCT) of approximately 100 eligible,
consenting daily smokers in the Southern Community Cohort Study (SCCS) who are willing to
make a quit attempt with medication and who reside in TN or MS. Participants will be
randomized 1:1:1 to 1 of 3 groups; (1) group one informs selection of medication with
information on nicotine metabolism; (2) group two offers a genetically-informed lung cancer
risk score, and (3) group 3 is Guideline-Based Care (GBC). All groups will be followed for 6
months. All RCT participants will receive FDA-approved smoking cessation medication, be
referred to the shared TN/MS state quitline, and be offered the NCI "Clearing the Air"
standard intervention. The primary outcome is feasibility of delivering the precision
interventions in the SCCS population, as evidenced by ability to recruit, engage, and retain
participants through end of study. Secondary outcomes, for which the study is not powered,
will include risk perceptions, use of quit aids, lung cancer screening among those who are
eligible, and smoking cessation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborators:
Meharry Medical College Tennessee State University